Adze-1.17.C.4.11

Adze-1.17.C.4.11 is a preclinical oncolytic immunotherapy developed by Adze Biotechnology, Inc., designed for the treatment of glandular and epithelial neoplasms[2]. It is part of the Adze-1.17 platform, which utilizes a conditionally replicative oncolytic virus to deliver immune-stimulatory payloads directly into solid tumors[1][5]. The mechanism involves selective virus-mediated tumor cell killing and modulation of the tumor microenvironment to promote systemic anti-tumor immunity[5]. Specifically, Adze-1.17.C.4.11 targets CD46 (as an inhibitor) and Desmoglein 2 (as a stimulant), aiming to enhance both direct oncolysis and immune activation against cancer cells[2].